<div id="readability-page-1"><div><div><table><thead><tr><th><span>Reporter Name</span></th><th><span>Relationship</span></th><th><span>Type</span></th><th><span>Amount</span></th><th><span>SEC Filing</span></th></tr></thead><tbody><tr><td><span>Larson-Green Julie</span></td><td><span>Director, 10% Owner</span></td><td><span>Sell</span></td><td><span>$128,348</span></td><td>Form 4</td></tr><tr><td><span>Landry Benjamin</span></td><td><span>General Counsel, 10% Owner</span></td><td><span>Sell</span></td><td><span>$72,327</span></td><td>Form 4</td></tr></tbody></table></div><p><span>Julie Larson-Green, a director and 10% owner of Health Catalyst, sold 47,997 shares of common stock on December 4, 2025, at a price of $2.6741 per share, totaling $128,348. Following the transaction, Larson-Green directly owns 73,573 shares of the company.</span></p><p><span>Benjamin Landry, General Counsel and 10% Owner at Health Catalyst, sold 27,425 shares of Common Stock on December 5, 2025, at a price of $2.6373 per share, totaling $72,327. After this sale, Landry directly owns 100,000 shares of Health Catalyst. The sale was executed under a pre-arranged trading plan adopted on March 1, 2025.</span></p></div></div>

HCAT

<p>Health Catalyst executives Julie Larson-Green and Benjamin Landry sold shares worth $128,348 and $72,327, respectively, in December 2025. Larson-Green sold 47,997 shares at $2.6741 per share, while Landry sold 27,425 shares at $2.6373 per share. These transactions were part of a pre-arranged trading plan adopted on March 1, 2025.</p>

Health Catalyst Executives Sell Shares